Cancer Genetics to Promote FHACT(TM) Test for Cervical Cancer at American Congress of Obstetricians and Gynecologists' Annual...
April 25 2014 - 8:00AM
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an
emerging leader in DNA-based cancer diagnostics, will be
participating in the Annual Clinical Meeting of the American
Congress of Obstetricians and Gynecologists (ACOG), being held
April 26-30 at the McCormick Place Convention Center in Chicago,
Illinois. ACOG is the premier gynecological conference in the U.S.
The conference hosts more than 200 exhibitors, and features more
than 400 original research posters and paper abstracts.
"This year's ACOG meeting is a great opportunity for us to
communicate the value of our proprietary FHACT™ test for the
management of cervical cancer to the clinical community and thought
leaders in this Congress," said Jane Houldsworth, Vice President of
Research and Development. "FHACT™ is a non-invasive genomic
test that can identify lesions caused by persistent HPV infection
and that are more likely to progress to a higher grade. By allowing
for a better screening of patients before referral for colposcopy,
the test can provide physicians with important information in
making treatment decisions and potentially reduce costs and
procedures that add to the U.S. healthcare costs."
This is the first year Cancer Genetics will have a commercial
presence at ACOG. Company representatives will be located at
Booth #939.
About FHACT™
FHACTTM (FISH-based HPV-Associated Cancer Test) is the only four
color FISH(1) probe that can be used for cervical cancer screening
as an additional test before referral for colposcopy. The
test uses a unique combination of genetic markers to detect genetic
abnormalities located at 3q, 5p, 20q and chromosome 7.
Research supporting the application of FHACT™ for the
detection of chromosomal abnormalities observed in cervical cancers
was published in the September 2013 issue of Gynecologic Oncology
http://dx.doi.org/10.1016/j.ygyno.2013.06.005. FHACT™ can be used
on the remnant liquid cytology (Pap smear) specimen (no
resampling). The test is offered at CGI's CLIA laboratory in
New Jersey.
(1) (fluorescence in
situ hybridization)
About Cancer Genetics
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer
diagnostics, servicing some of the most prestigious medical
institutions in the world. Our tests target cancers that are
difficult to diagnose and predict treatment outcomes. These cancers
include hematological, urogenital and HPV-associated cancers. We
also offer a comprehensive range of non-proprietary
oncology-focused tests and laboratory services that provide
critical genomic information to healthcare professionals, as well
as biopharma and biotech companies. Our state-of-the-art reference
lab is focused entirely on maintaining clinical excellence and is
both CLIA certified and CAP accredited and has licensure from
several states including New York State. We have established strong
research collaborations with major cancer centers such as Memorial
Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National
Cancer Institute. For further information, please see
www.cancergenetics.com.
Forward Looking Statements: This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
pertaining to future financial and/or operating results, future
growth in research, technology, clinical development and potential
opportunities for Cancer Genetics, Inc. products and services,
along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical
fact (including, but not limited to, statements that contain words
such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, risks
of cancellation of customer contracts or discontinuance of trials,
uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, maintenance
of intellectual property rights and other risks discussed in the
Company's Form 10-K for the year ended December 31, 2013 and other
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. Cancer
Genetics disclaims any obligation to update these forward-looking
statements.
CONTACT: Investor Relations
Michael Rice
Life Science Advisors LLC
646-597-6979
Media Relations
RedChip Companies, Inc.
Paul Kuntz, 800-733-2447, ext. 105
paul@redchip.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2023 to Jul 2024